Soumitra Sudip Bhuyan

Soumitra Sudip Bhuyan

Auto-generated profile, based on publicly available information

Soumitra Sudip Bhuyan

Edward J. Bloustein School of Planning and Public Policy, Rutgers University, New Brunswick, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2016 in Journal of Medical Systems
Verified
Journal Article
Closed access
PDF file
SBSoumitra S. Bhuyan
Soumitra S. Bhuyan
NLNing Lu
Ning Lu
ACAastha Chandak
Aastha Chandak
HKHyunmin Kim
Hyunmin Kim
DWDavid Wyant
David Wyant
CCCyril F. Chang
Cyril F. Chang

16 January 2025 in Journal of Medical Systems
Verified
Journal Article
Open access
PDF file
SBSoumitra S. Bhuyan
Soumitra S. Bhuyan
VSVidyoth Sateesh
Vidyoth Sateesh
NMNaya Mukul
Naya Mukul
AGAlay Galvankar
Alay Galvankar
AMAsos Mahmood
Asos Mahmood
JSJim Samuel
Jim Samuel
Generative Artificial Intelligence (Gen AI) has transformative potential in healthcare to enhance patient care, personalize treatment options, train healthcare professionals, and advance medical research. This paper examines various clinical and non-clinical applications of Gen AI. In clinical settings, Gen AI supports the creation of customized treatment plans, generation of synthetic data, analysis of medical images, nursing workflow management, risk prediction, pandemic preparedness, and population health management. By automating administrative tasks such as medical documentations, Gen AI has the potential to reduce clinician burnout, freeing more time for direct patient care. Furthermore, application of Gen AI may enhance surgical outcomes by providing real-time feedback and automation of certain tasks in operating rooms. The generation of synthetic data opens new avenues for model training for diseases and simulation, enhancing research capabilities and improving predictive accuracy. In non-clinical contexts, Gen AI improves medical education, public relations, revenue cycle management, healthcare marketing etc. Its capacity for continuous learning and adaptation enables it to drive ongoing improvements in clinical and operational efficiencies, making healthcare delivery more proactive, predictive, and precise.

14 November 2017 in Journal of Cancer Education
Verified
Journal Article
Closed access
PDF file
HKHyunmin Kim
Hyunmin Kim
JGJoy Goldsmith
Joy Goldsmith
SSSoham Sengupta
Soham Sengupta
AMAsos Mahmood
Asos Mahmood
MPM. Paige Powell
M. Paige Powell
SBSoumitra S. Bhuyan
Soumitra S. Bhuyan

1 June 2017 in Health Policy and Technology
Verified
Journal Article
Closed access
SBSoumitra S. Bhuyan
Soumitra S. Bhuyan
HKHyunmin Kim
Hyunmin Kim
OIOluwaseyi O. Isehunwa
Oluwaseyi O. Isehunwa
NKNaveen Kumar
Naveen Kumar
JBJay Bhatt
Jay Bhatt
DDDipankar Dasgupta
Dipankar Dasgupta

1 December 2015 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
TLTao Liu
Tao Liu
XLXiaobo Li
Xiaobo Li
SYShuo You
Shuo You
SBSoumitra S. Bhuyan
Soumitra S. Bhuyan
Lei DongLei Dong
Lei Dong
AMD3100, also known as plerixafor, was originally developed as an anti-human immunodeficiency virus (HIV) drug, and later characterized as a C-X-C chemokine receptor type 4 (CXCR4) antagonist. Previous reviews have focused on the application of AMD3100 in the treatment of HIV, but a comprehensive evaluation of AMD3100 in the treatment of leukemia, solid tumor, and diagnosis is lacking. In this review, we broadly describe AMD3100, including the background, functional mechanism and clinical applications. Until the late 1990s, CXCR4 was known as a crucial factor for hematopoietic stem and progenitor cell (HSPC) retention in bone marrow. Subsequently, the action and synergy of plerixafor with Granulocyte-colony stimulating factor (G-CSF) led to the clinical approval of plerixafor as the first compound for mobilization of HSPCs. The amount of HSPC mobilization and the rapid kinetics promoted additional clinical uses. Recently, CXCR4/CXCL12 (C-X-C motif chemokine 12) axis was found to be involved in a variety of roles in tumors, including leukemic stem cell (LSC) homing and signaling transduction. Thus, CXCR4 targeting has been a treatment strategy against leukemia and solid tumors. Understanding this mechanism will help shed light on therapeutic potential for HIV infection, inflammatory diseases, stem-cell mobilization, leukemia, and solid tumors. Clarifying the CXCR4/CXCL12 axis and role of AMD3100 will help remove malignant cells from the bone marrow niche, rendering them more accessible to targeted therapeutic agents.

18 January 2017 in Journal of Medical Systems
Verified
Journal Article
Closed access
PDF file
HKHyunmin Kim
Hyunmin Kim
MPM. Paige Powell
M. Paige Powell
SBSoumitra S. Bhuyan
Soumitra S. Bhuyan